What are the effects, mechanisms of action, and indications of zaleplon, temazepam, and zolpidem?

Comparison of Zaleplon, Temazepam, and Zolpidem

All three medications are recommended by the American Academy of Sleep Medicine for treating insomnia in adults, but they differ significantly in their pharmacokinetic profiles and specific indications: zaleplon is best for sleep-onset insomnia only due to its ultrashort half-life (1 hour), zolpidem treats both sleep-onset and sleep-maintenance insomnia with an intermediate half-life (2.5 hours), and temazepam addresses both sleep-onset and maintenance problems with a longer half-life (8-24 hours) but carries higher risk of residual morning sedation. 1

Mechanisms of Action

All three agents work through the GABA-benzodiazepine receptor complex, but with important distinctions:

• Zaleplon and Zolpidem (non-benzodiazepine "Z-drugs"): Selectively bind to the omega-1 (α1) subunit of GABA-A receptors, which mediates sedative effects while minimizing effects on memory and cognition associated with omega-2 receptors 2, 3. This selective binding explains their more favorable cognitive side-effect profile compared to traditional benzodiazepines.

• Temazepam (benzodiazepine): Non-selectively binds to both omega-1 and omega-2 receptor sites, producing sedation but also affecting memory and cognitive function more significantly 3, 4.

The clinical implication: Z-drugs generally preserve psychomotor performance and memory better than benzodiazepines, with impairment primarily limited to peak plasma concentration periods 3.

Pharmacokinetics and Clinical Effects

Zaleplon

• Half-life: ~1 hour (ultrashort) 2, 5
• Time to peak effect: 0.5-1.0 hours 6
• Oral clearance: ~4300 mL/min (very rapid) 5
• Clinical profile: Reduces sleep latency but has minimal effect on wake after sleep onset (WASO) or total sleep time 7, 2
• Residual effects: Virtually no morning sedation due to rapid elimination 7

Zolpidem

• Half-life: ~2.5 hours (short-intermediate) 8, 5
• Time to peak effect: 1.5-2.0 hours 6
• Oral clearance: 340-380 mL/min 5
• Clinical profile: Reduces sleep latency AND improves sleep maintenance 1
• Residual effects: Minimal morning impairment in most patients, but FDA mandates lower doses in women and elderly due to slower metabolism 8

Temazepam

• Half-life: 8-24 hours (intermediate-long) 7
• Time to peak effect: 2-3 hours 6
• Clinical profile: Improves both sleep onset and maintenance, with longer duration of action 1
• Residual effects: More likely to cause morning sedation and psychomotor impairment compared to Z-drugs 7, 9

Indications per AASM Guidelines

Based on the 2017 AASM Clinical Practice Guideline 1:

• Zaleplon (10 mg): Suggested for sleep-onset insomnia only (WEAK recommendation)
• Zolpidem (10 mg): Suggested for both sleep-onset and sleep-maintenance insomnia (WEAK recommendation)
• Temazepam (15 mg): Suggested for both sleep-onset and sleep-maintenance insomnia (WEAK recommendation)

Clinical Decision Algorithm

For sleep-onset insomnia only:

• Choose zaleplon (10 mg) or zolpidem (10 mg)
• Zaleplon preferred if: Patient needs to take medication in middle of night, concerns about morning sedation, or very short sleep window available
• Zolpidem preferred if: Some sleep maintenance issues also present

For sleep-maintenance insomnia (with or without onset difficulty):

• Choose zolpidem (10 mg) or temazepam (15 mg)
• Zolpidem preferred if: Patient needs to function early morning, elderly patient, or concerns about residual sedation
• Temazepam preferred if: Longer duration of action needed, patient has failed Z-drugs, or cost is a major factor

Special populations:

• Elderly: Reduce all doses by 50%; strongly favor zaleplon or low-dose zolpidem over temazepam due to fall risk and cognitive impairment 8, 10
• Women: Use lower zolpidem doses (5 mg) due to slower metabolism 8
• Substance abuse history: Consider zaleplon or zolpidem over benzodiazepines, though all carry dependence risk 7

Comparative Efficacy

Direct comparison studies show that at equipotent doses, all three produce similar magnitude of hypnotic effects, but with different time courses 6, 5:

• Zaleplon 20 mg ≈ Zolpidem 10 mg in overall potency 5
• Zolpidem 20 mg produces significantly greater effects than other treatments 5
• Temazepam 20 mg provides longer and qualitatively better sleep than zaleplon 10 mg 9

Important Safety Considerations

All three medications carry risks for 7:

• Cognitive and behavioral changes including complex sleep behaviors
• Driving impairment (particularly within 8 hours of dosing)
• Falls and fractures (especially in elderly)
• Potential for tolerance and dependence with chronic use
• Rebound insomnia upon discontinuation

Critical caveat: The 2008 and 2017 AASM guidelines emphasize that pharmacotherapy should be supplemented with cognitive-behavioral therapy for insomnia (CBT-I) when possible, and efforts should be made to use the lowest effective dose and taper when conditions allow 7. All recommendations are WEAK strength, reflecting the limited long-term efficacy and safety data for these agents.